B1 Cont



where X is CH_2,

R^7, R^8 and R^9 are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl-$(CH_2)_m$-, aryl-$(CH_2)_m$- and heteroaryl-$CH_2)_m$-,

where m is 0 or an integer from 1 to 6;

R^6, R^{10}, R^{11}, and R^{12} are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl-$(CH_2)_p$-, aryl-$(CH_2)_p$- and heteroaryl-$CH_2)_p$-; and

R^4 is OH, Oalkyl, O-$(CH_2)_p$-heteroaryl,

A1 Cont



, -O-$(CH_2)_p$-aryl or or $NR_1(R_2)$ where R_1 and R_2 are independently H, alkyl, aryl, aryl-$(CH_2)_p$ or heteroaryl;

R^{14} is hydrogen, alkyl, cycloalkyl, or phenyl;

R^{15} is hydrogen, alkyl, alkoxy or phenyl; and

R^{16} is alkyl or aryl-$(CH_2)_m$-.--

--6. (Amended) The compound as defined in Claim 1 wherein A is

A2

Broad Reason





--7. (Amended) The compound as defined in Claim [6] 1 wherein A is





--.

--12. (Amended) A pharmaceutical composition comprising a [therapeutically effective amount of a] compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.--

--13. (Amended) The pharmaceutical composition as defined in Claim 12 useful in the treatment of [cardiovascular diseases such as] hypertension and/or congestive heart failure.--

--14. (Amended) A method of treating [a cardivascular disease such as] hypertension and/or congestive heart failure, which comprises administering to a mammalian species a therapeutically effective amount of a composition as defined in Claim 12.--

--15. (Amended) The compound as defined in Claim 1 which is











or a pharmaceutically acceptable salt thereof.--